Early Versus Late Catheter Removal in Patients With Acute Urinary Retention Secondary to BPH Under Tamsulosin Treatment

Early Versus Late Catheter Removal in Patients With Acute Urinary Retention Secondary to Benign Prostatic Hyperplasia Under Tamsulosin Treatment

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03280420

Enrollment

Registered

2017-09-12

Start date

2017-03-12

Completion date

2017-09-16

Last updated

2017-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BPH With Urinary Obstruction

Keywords

Acute urinary retention, BPH, TWOC, Tamsulosin

Brief summary

The aim of this work is to compare between early (3days) and late(7days) removal of urinary catheter after acute urine retention in patients with Benign Prostatic Hyperplasia under Tamsulosin treatment.

Detailed description

This is a prospective randomized study, Men with acute urinary retention secondary to benign prostatic hyperplasia were catheterized and then, if they fulfilled the entry criteria, were randomly assigned to receive 0.4 mg tamsulosin hydrochloride for three days or seven days, After that the catheter was removed and the ability to void unaided assessed.

Interventions

PROCEDUREEarly catheter removal

Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 3 days. After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy.

PROCEDURELate catheter removal

Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 7 days. After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

All patients were catheterized and received urinary antiseptic and then randomly divided into two groups : Group I :30 patients received Tamsulosin 0.4 mg once daily and catheter removed after 3 days. Group II :30 patients received Tamsulosin 0.4 mg once daily and catheter removed after 7 days.

Eligibility

Sex/Gender

MALE

Healthy volunteers

Yes

Inclusion criteria

* Patients having first attack of acute urinary retention secondary to BPH.

Exclusion criteria

* Renal impairment. * Suspected urethral stricture. * Neurogenic bladder. * Cancer prostate. * Medically induced retention. * Previous use of alpha blockers. * History of drug hypersensitivity or allergy to Tamsulosin.

Design outcomes

Primary

Measure	Time frame	Description
The duration for trial without catheter	6 Months	To determine the optimum period to remove catheter in patients complaining of acute urinary retention with benign prostatic hyperplasia.

Secondary

Measure	Time frame	Description
Factor affecting trial without catheter	6 Months	To evaluate the role of the following in trial without catheter patient's age prostate size residual urine volume prostatic specific antigen (PSA)

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026